Novel approaches for molecular targeted therapy against hepatocellular carcinoma
Author:
Affiliation:
1. Department of Gastroenterology and Hepatology, Graduate School of Medicine; Kyoto University; Kyoto Japan
2. Department of Gastroenterology and Hepatology; Osaka Red Cross Hospital; Osaka Japan
Publisher
Wiley
Subject
Infectious Diseases,Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.13181/fullpdf
Reference82 articles.
1. Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications;Sartorius;Cancer Epidemiol,2015
2. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma;Bruix;Gastroenterology,2016
3. Hepatocellular carcinoma;Forner;Lancet,2012
4. Current status of hepatocellular carcinoma in Japan;Ikeda;Chin Clin Oncol,2013
5. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008
Cited by 66 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials;Biomedicine & Pharmacotherapy;2024-10
2. Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A category: A multicenter study;Hepatology Research;2024-07-02
3. GDF15: Immunomodulatory Role in Hepatocellular Carcinoma Pathogenesis and Therapeutic Implications;Journal of Hepatocellular Carcinoma;2024-06
4. To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors;Current Topics in Medicinal Chemistry;2023-12
5. ACTB may serve as a predictive marker for the efficacy of lenvatinib in patients with HBV-related early-stage hepatocellular carcinoma following partial hepatectomy: a retrospective cohort study;Journal of Gastrointestinal Oncology;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3